Golar LNG Limited Interim results for the period ended March 31 2024
May 28, 2024 07:03 ET
|
Golar LNG
Highlights and subsequent events Golar LNG Limited (“Golar” or “the Company”) reports Q1 2024 (“Q1” or “the quarter”) Net income attributable to Golar of $55 million inclusive of $6 million of...
Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association Congress
May 28, 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
– Results from Preclinical Model of Hyperphosphatemia Demonstrate the Relative Potency of OLC Compared to Tenapanor – – Oral UNI-494 Shows Promise in a Preclinical Model as a Potential Candidate...
Olema Oncology to Participate in Upcoming Investor Conferences in June
May 28, 2024 07:03 ET
|
Olema Oncology
SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Ocugen Set to Join Russell 3000® Index Effective June 28, 2024
May 28, 2024 07:02 ET
|
Ocugen
MALVERN, Pa., May 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria
May 28, 2024 07:02 ET
|
Allakos Inc.
– Top-line Phase 1 CSU results expected at year end 2024 – SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK006 for the...
Sol-Gel Announces Receipt of Nasdaq Minimum Price Notice
May 28, 2024 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel Announces Receipt of Nasdaq Minimum Price Notice
Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting
May 28, 2024 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC
May 28, 2024 07:00 ET
|
Merus N.V.
67% response rate observed among 24 evaluable patients Conference Call on Tuesday, May 28th at 8 a.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Merus N.V....
Vorläufige Ergebnisse von Merus zu Petosemtamab in Kombination mit Pembrolizumab zeigen robuste Ansprechrate und günstiges Sicherheitsprofil bei Erstlinienbehandlung von rezidivierendem/metastasierendem HNSCC
May 28, 2024 07:00 ET
|
Merus N.V.
67 % Ansprechrate bei 24 auswertbaren Patienten beobachtet Telefonkonferenz am Dienstag, 28. Mai um 8 Uhr Eeastern Time UTRECHT, Niederlande und CAMBRIDGE, Massachusetts, May 28, 2024 (GLOBE...
FactSet Schedules Third Quarter 2024 Earnings Call
May 28, 2024 07:00 ET
|
FactSet Research Systems Inc.
NORWALK, Conn., May 28, 2024 (GLOBE NEWSWIRE) -- FactSet (NYSE: FDS | NASDAQ: FDS), a global financial digital platform and enterprise solutions provider, announced today that it will release its...